This #WorldHepatitisDay, Vir is highlighting the unmet needs of the approximately 254 million people worldwide living with an increased risk of deadly liver cancer caused by chronic #hepatitisB and #hepatitisdelta viruses. Testing and treatment may help improve the chances of living a long and healthy life. To learn if you’re at risk, take the first step by getting tested today.
About us
Vir Biotechnology, Inc. (in Europe, Humabs BioMed, https://bit.ly/46lQGN2) is an immunology company focused on powering the immune system to address unmet patient needs in infectious disease and beyond. Our powerful R&D engine combines our proprietary monoclonal antibody (mAb) platform with machine learning and artificial intelligence-enhanced capabilities, enabling us to engineer our rich database of human antibodies and deliver transformative medicines for diseases with significant global burden. Our current pipeline consists of multiple clinical candidates targeting hepatitis B and hepatitis delta viruses and human immunodeficiency virus, including a potential functional cure for chronic hepatitis B and treatment for chronic hepatitis delta. Our portfolio of broad, potent investigational monoclonal antibodies also targets influenza A and B viruses, COVID-19, respiratory syncytial virus/human metapneumovirus and human papillomavirus, and our investigational T cell vaccine aims to prevent HIV. Explore our full pipeline: https://bit.ly/3tr7FPm We collaborate with some of the world’s leaders in industry as well as government agencies and non-profit organizations enabling us to rapidly advance cutting-edge scientific discoveries and innovative technologies with the potential to benefit people around the world. We are proud to have been ranked the fastest-growing company in North America on the 2022 Deloitte Technology Fast 500™. Join us as we pursue our mission to transform lives. It has come to our attention that there have been various recruitment scams targeting job seekers on LinkedIn. Vir Biotechnology, Inc. is committed to your privacy and will never request sensitive personal information including banking details through email, text message, social media or video software platforms. We also will never request a financial commitment from a candidate as part of the application process. Learn more about Vir’s recruiting process: https://bit.ly/461EgJN
- Website
-
http://www.vir.bio
External link for Vir Biotechnology, Inc.
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- San Francisco, California
- Type
- Public Company
- Founded
- 2016
Locations
-
Primary
1800 Owens St
Suite 900
San Francisco, California 94158, US
-
Via Mirasole 1
Bellinzona, Ticino 6500, CH
Employees at Vir Biotechnology, Inc.
Updates
-
Good morning! We’re joining our fellow Virites at Crissy Field in @SanFrancisco for the 3rd annual #HepBHero 5K Run/Walk. #HepatitisB takes a life every 30 seconds. That number can be decreased by increasing awareness of testing and vaccination.
-
-
We’re thrilled to partner with SF Hep B Free for the Hero Run/Walk again! Chronic #hepatitisB affects ~254 million people worldwide, but with proactive testing and treatment, together we can improve the chances of millions to lead long, healthy lives. Join us Saturday and be a #HEPBHERO! https://bit.ly/4bepEbR
-
Chronic #Hepatitis Delta is often overlooked yet remains the most severe form of viral hepatitis. Despite affecting at least 12 million people worldwide, many remain undiagnosed due to lack of awareness and inadequate screening. As we approach #WorldHepatitisDay July 28, Dr. Mark Eisner, Chief Medical Officer at Vir, sheds light on these issues and more. Read his article here. #hepd #hepatitisdelta
Unveiling the Silent Threat: Surprising Facts About Chronic Hepatitis Delta
Vir Biotechnology, Inc. on LinkedIn
-
Congratulations to Jenny Gumm, our Chief Human Resources Officer, for being recognized with Menttium's “15 Over 15 Mentoring Partnerships Award”. This honor is given to mentors dedicated to nurturing the next generation of leaders. We’re so proud to have Jenny as part of Vir’s Executive Management Team! Learn more about the honor here: https://bit.ly/3W7TglD
-
-
Thank you Moira Gunn for featuring Vir’s hepatitis delta story and welcoming our CEO onto your program to discuss the recent progress we’ve made towards developing a treatment for people living with chronic hepatitis delta. https://lnkd.in/gvdurTMG #hepatitisdelta #hepatitisd #hepD #HepCantWait
BioTech Nation ... with Dr. Moira Gunn | A Dual Approach to Combatting Hepatitis... Dr. Marianne De Backer, CEO at Vir Biotechnology
biotechnation.com
-
We are thrilled to announce that the U.S. FDA has cleared our IND application and granted Fast Track designation for our investigational combination therapy, tobevibart and elebsiran, for the treatment of chronic #hepatitis delta infection. Learn more here: https://bit.ly/4eFyNx5 #hepatitisdelta #hepatitisD #hepD
-
This #PrideMonth we’re proud to elevate the voices within our LGBTQIA+ community. At Vir, we believe it’s vital to cultivate an environment that fosters our virtue of authenticity. We celebrate our employees’ ability to be genuine, be open, and be themselves! #VirPride #Pride2024
-
At Vir, we believe that true innovation comes from diversity of thought and experiences. #Juneteenth serves as a poignant reflection of our commitment to fostering a culture that embraces and uplifts all communities. Together, let's make strides toward lasting change. #DiversityAndInclusion
-
Vir Biotechnology, Inc. reposted this
Chief Technology Officer (CTO), EVP Technical Operations & Quality at Vir Biotechnology & NIBRT Board member.
I’m looking forward to participating on a panel discussion this week on “Getting to Regulatory Approval” at the @Longwood Healthcare Leaders Spring MIT forum. This meeting is Co-hosted by Professors Phil Sharp and Bob Langer and held at MIT’s Koch Institute, June 17-18, and includes a broad spectrum of topics affecting the biopharma ecosystem. @longwoodhealthcareleaders @longwoodfund #longwoodhealthcareleaders #virbio
-